Overview

Since 2002, CME Outfitters has delivered over 1,400 innovative evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. CME Outfitters focuses on delivering education to primary care, specialty audiences and community-based clinicians with strong expertise in neuroscience, gastroenterology, dermatology, rheumatology, immunology, virology, transplant, and cardiology. CME Outfitters is certified as a women’s business enterprise through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third-party certifier of businesses owned and operated by women in the United States.


@MondayNightIBD OnDemand: Addressing the Cases That Challenge Your Practice

Statement of Need Gastroenterologists are trailblazers in health care social media, and #MondayNightIBD (#MNIBD) has harnessed that energy to establish gastroenterologists as not just social media influencers but as clinical practice influencers as well. #MNIBD is not just a weekly social media conversation - it is an international platform that is moving the field forward by crowdsourcing th...
CME Outfitters

A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience

Statement of Need Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD effects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepat...
CME Outfitters

At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus

Statement of Need Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significant morbidity and mortality. In 2015, there were 257 million people worldwide infected with HBV. In 2016, only 10.5% were diagnosed, with only 16.7% receiving treatment, and without intervention, there are 19 million deaths anticipated by the end of 2020. These numbers are startling as they exist...
CME Outfitters

Biomarkers for Diagnosis and Prognosis of MS

It is an exciting period for the clinical management of multiple sclerosis (MS), with an expanding treatment landscape and recent approval of new disease-modifying therapies (DMTs) for both relapsing and progressive MS. The Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting, the largest MS meeting in North America, features the latest information on cutting-edge research finding...
CME Outfitters

Clinical Insights on Recent Advances in Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a leading, fatal, autosomal recessive disorder that affects approximately one in 10,000 live births. Nusinersen was approved as the first targeted therapy for SMA, and since its groundbreaking approval data has been published that demonstrates its efficacy for both infantile- and later-onset SMA populations. Additionally, recent guidelines were published that pro...
CME Outfitters

Current and Emerging Therapies for Schizophrenia: How MOA Affects Clinical Outcomes

Clinical trial data that addresses the safety and efficacy of antipsychotics is continuously emerging, with a focus on optimizing the management of schizophrenia. These data include the identification of strategies with novel mechanisms of action (MOAs) to effectively resolve symptoms and promote recovery while minimizing metabolic effects. The second episode of this schizophrenia CMEOcast p...
CME Outfitters

Don’t Snooze on the Latest Evidence on Excessive Daytime Sleepiness in OSA and Narcolepsy: An Expert-Guided Tour of the Sleep 2019 Annual Meeting

Residual excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) and narcolepsy is a common, debilitating condition that compromises patients' overall health, wellness, and safety. The field of sleep medicine is rapidly evolving to address the unmet needs of EDS as novel treatment options become available. In this CME Outfitters dynamic, interactive infographic, expe...
CME Outfitters

Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD

Step therapy requirements have limited patient access to FDA-approved, anti–vascular endothelial growth factor (VEGF) agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systematic and clinically supported appeals that ensure uninterrupte...
CME Outfitters

Improving the Quality of Care for Patients with Atopic Dermatitis: Integrating Measurement-Based Tools Into Your Clinical Practice

Statement of Need Attitudes about atopic dermatitis are evolving with the emergence of new and effective treatments. With the average dermatologist having not enjoyed caring for patients with AD for decades, there is little to no consensus in current practice about validated tools to assess and monitor the severity of the diseases and no consistent use of diagnostic or assessment tools. This la...
CME Outfitters

Keeping the Patient in the Center in AMD Care

Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50, but the development of agents that target vascular endothelial growth factor (VEGF) has revolutionized its treatment. There are currently two FDA-approved agents (ranibizumab and aflibercept) and one off-label anti-VEGF agent (bevacizumab) being used to treat patients with AMD, and data from eme...
CME Outfitters

Long-Acting Injectables for Schizophrenia: An Effective, Yet Often Underutilized Tool for Rapid Symptom Reduction and Restoration of Function

Schizophrenia is a serious and debilitating disorder that often poses a considerable challenge to clinicians. While long-acting injectables (LAIs) have emerged as a viable means to address patient nonadherence – often a component of schizophrenia management – clinicians often fail to implement the use of LAIs. Many times this is due to clinicians not being aware of updates such as the introd...
CME Outfitters

Minimizing the Burden of Prior Authorization in AMD Through Actionable Strategies and Improved Communication

The development of anti–vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of age-related macular degeneration (AMD). Nevertheless, optimal management of AMD is impeded by challenges in access to FDA-approved therapies. Step therapy, a type of prior authorization (PA) instituted by the payer, mandates that more cost-effective therapies be used before more expensi...
CME Outfitters

Navigating the New Psoriasis Guidelines: Implications for Clinical Practice

Statement of Need: The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have recently released new joint guidelines that outline best practices for the management of psoriasis (PsO) with biologics, the need for awareness and attention to comorbidities, and guidelines for pediatric PsO treatment. Clinicians must ensure that they are aware of these guidelines and ...
CME Outfitters

Navigating Through the Latest Advances in Monoclonal Antibodies: Translating Evidence to the Care of Patients with Psoriasis

Recent years have seen an increase in the number of therapeutic monoclonal antibodies (mAbs) that are available to treat a variety of conditions caused by immune-mediated chronic inflammation such as psoriasis. Health care professionals are often presented with complex and conflicting information surrounding concepts of mAb production and immunogenicity; therefore, there is a significant need fo...
CME Outfitters

Recent Clinical Trial Data on the Safety and Efficacy of Current and Emerging Therapies to Optimize Schizophrenia Management

Safe and effective treatments for schizophrenia are imperative to optimizing personalized therapy, which helps in reducing relapse and promoting functional recovery in patients with schizophrenia. Emerging data on reducing symptoms, maintaining effective therapy over long-term periods, and minimizing treatment-related metabolic side effects can guide clinicians in choosing the best therapies for...
CME Outfitters

What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies

Statement of Need Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. While there are currently no approved therapies for the treatment of NASH, several targeted ...
CME Outfitters

Zooming In on the Education and Empowerment of Patients in AMD Care

FDA-approved agents that target vascular endothelial growth factor (VEGF) constitute important elements of optimal management of AMD. Prior authorization (PA) requirements limit patient access to these therapies. Navigating the PA process can be frustrating for patients, and may result in treatment abandonment leading to suboptimal outcomes. Hence, there is a need for patients to become advocate...
CME Outfitters

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.